Theranostics 2021; 11(8):3963. doi:10.7150/thno.58558

Erratum

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Jiang-Kai Dong1,2,#, Hui-Min Lei1,2,#, Qian Liang1,2,#, Ya-Bin Tang1,2, Ye Zhou1,2, Yang Wang1,2, Shengzhe Zhang3, Wen-Bin Li1, Yunguang Tong4,5, Guanglei Zhuang3, Liang Zhang1,2, Hong-Zhuan Chen1,2,✉, Liang Zhu1,2,✉, Ying Shen1,2,✉

1. Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
2. Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China
3. State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
4. Basic Medical College, Xinxiang Medical University, Xinxiang 453003, Henan, China
5. Department of Medicine, Cedars-Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, CA 90048, United States
#These authors contributed equally to the manuscript

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Dong JK, Lei HM, Liang Q, Tang YB, Zhou Y, Wang Y, Zhang S, Li WB, Tong Y, Zhuang G, Zhang L, Chen HZ, Zhu L, Shen Y. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum. Theranostics 2021; 11(8):3963. doi:10.7150/thno.58558. Available from https://www.thno.org/v11p3963.htm

File import instruction

Corrected-article in Theranostics, Volume 8, 1808